Multi-Centre, Prospective, Observational Study of Patient Reported Outcomes in Patients Diagnosed With Chronic Migraine and Treated With OnabotulinumtoxinA for Injection (BOTOX®) (PREDICT)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 01 Aug 2017
At a glance
- Drugs Botulinum toxin A (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Acronyms PREDICT
- Sponsors Allergan
- 25 Jul 2017 Planned primary completion date changed from 1 Dec 2016 to 30 Dec 2018.
- 19 Dec 2016 Status changed from recruiting to active, no longer recruiting.
- 12 Oct 2016 Planned End Date changed from 1 Sep 2018 to 1 Dec 2018.